Bailard’s Lineage Cell Therapeutics LCTX Stock Holding History

Bailard’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-63,400	Closed	-$155K	–	772
2021 Q4	$155K	Buy	+63,400	New	+$148K	﹤0.01%	701

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bailard's LCTX Position: Q1 2022 in Review

Bailard sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 63,400 shares — an estimated $155K sold.

Bailard first reported a position in LCTX in Q4 2021 and held it in 1 quarter. The position peaked at $155K in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

Bailard reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
Bailard sold 63,400 Lineage Cell Therapeutics shares in Q1 2022, an estimated $155K.
Bailard first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 1 quarter.
Bailard's Lineage Cell Therapeutics position peaked at $155K in Q4 2021.
110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.